

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first-class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, facsimile transmitted to the U.S. Patent and Trademark Office at (571) 273-8300, or electronically submitted via EFS on February 16, 2012.

PATENT

Attorney Docket No.: PAT053246-US-CNT02

By:


Karen Zielen

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Steve PABOOJIAN, et al	Examiner:	Michael G. MENDOZA
Serial No.: 09/731,318	Art Unit:	3734
Filed: December 6, 2000	Confirmation No.:	1028
For:	RECEPTACLES TO FACILITATE THE EXTRACTION OF POWDERS	

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, applicants wish to call the Examiner's attention to the references cited on the attached form PTO-1449. Copies of the foreign publications and non-patent references are being provided herewith. For those foreign patent documents that are not in the English language, applicants have included copies of equivalent references as listed in their bibliographic data, a copy of which is also enclosed.

It is believed this disclosure complies with the requirements of 37 C.F.R. §§ 1.56, 1.97, 1.98, and the Manual of Patent Examining Procedure § 609; specifically, § 1.97(c)(2) which states:

1.97(c)(2)

(c) An information disclosure statement shall be considered by the Office if filed after the period specified in paragraph (b) of this section, provided that the information disclosure statement is filed before the mailing date of any of a final action under § 1.13, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application, and it is accompanied by ...:

(2) The fee set forth in § 1.17(p). Therefore, we hereby submit the fee under 37 C.F.R. §1.17(p).

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application, and would appreciate the Examiner's initialing and returning the form PTO-1449 to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement under 37 C.F.R § 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these citations constitute prior art under 35 U.S.C. § 102.


The Commissioner is hereby authorized to charge any additional fees (or credit any overpayment) associated with this communication and which may be required under 37 CFR §§ 1.16 and 1.17 to Deposit Account No. 19-0134.

Application No.: 09/731,318
Supplemental Information Disclosure Statement

Attorney Docket No.: PAT053246-US-CNT02

Respectfully submitted,

Date: February 16, 2012

By: 
Michael J. Mazza
Registration No. 30,775

Novartis Pharmaceuticals Corporation
Building 101
One Health Plaza
East Hanover, NJ 07936-1080
Fax: (973) 781-8064